tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Promising Growth and Strategic Innovation Drive Buy Rating for Day One Biopharmaceuticals

Promising Growth and Strategic Innovation Drive Buy Rating for Day One Biopharmaceuticals

Analyst Andres Y. Maldonado from H.C. Wainwright reiterated a Buy rating on Day One Biopharmaceuticals and decreased the price target to $25.00 from $36.00.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Andres Y. Maldonado has given his Buy rating due to a combination of factors that highlight the promising future of Day One Biopharmaceuticals. The company’s key product, OJEMDA, has shown significant growth potential with $33.6 million in net sales in the second quarter of 2025 and over 1,600 prescriptions in the first eight months post-approval. This growth is supported by widespread BRAF-fusion testing, prescriber confidence in the drug’s tolerability, and its convenient once-weekly dosing schedule. Additionally, updated data presented at ASCO 2025 indicate that OJEMDA can be used over extended periods without long-term endocrine issues, further solidifying its position in the market.
Furthermore, the favorable safety profile of OJEMDA, particularly its low-grade rash side effects, positions it well against competitors like MEK inhibitors. The ongoing Phase 3 FIREFLY-2 study aims to expand its use into newly diagnosed pediatric low-grade glioma cases, which represents a significantly larger market. Beyond OJEMDA, Day One Biopharmaceuticals is also advancing other promising projects, such as the DAY301 antibody-drug conjugate, which underscores the company’s strategic focus on growth and innovation in oncology. These factors collectively reinforce the Buy rating, despite a modest revision in the long-term revenue forecast.

In another report released today, Needham also maintained a Buy rating on the stock with a $16.00 price target.

Disclaimer & DisclosureReport an Issue

1